{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:02:28Z","timestamp":1787792548658,"version":"build-2784847793"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012128","name":"Austin Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012128","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Introduction:<\/jats:bold>\n                    <jats:italic>Ex vivo<\/jats:italic>\n                    and\n                    <jats:italic>in vitro<\/jats:italic>\n                    diagnostics, such as interferon-\u03b3 (IFN-\u03b3) release enzyme linked ImmunoSpot (ELISpot) and flow cytometry, are increasingly employed in the research and diagnostic setting for severe T-cell mediated hypersensitivity. Despite an increasing use of IFN-\u03b3 release ELISpot for drug causality assessment and utilization of a range of antimicrobial concentrations\n                    <jats:italic>ex vivo<\/jats:italic>\n                    , data regarding antimicrobial-associated cellular cytotoxicity and implications for assay performance remain scarcely described in the literature. Using the measurement of lactate dehydrogenase (LDH) and the 7-AAD cell viability staining, we aimed via an exploratory study, to determine the maximal antimicrobial concentrations required to preserve cell viability for commonly implicated antimicrobials in severe T-cell mediated hypersensitivity.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Method:<\/jats:bold>\n                    After an 18-h incubation of patient peripheral blood monocytes (PBMCs) and antimicrobials at varying drug concentrations, the cell cytotoxicity was measured in two ways. A colorimetric based assay that detects LDH activity and by flow cytometry using the 7-AAD cell viability staining. We used the PBMCs collected from three healthy control participants with no known history of adverse drug reaction and two patients with a rifampicin-associated drug reaction with eosinophilia and systemic symptoms (DRESS), confirmed on IFN-\u03b3 ELISpot assay. The PBMCs were stimulated for the investigated drugs at the previously published drug maximum concentration (\n                    <jats:italic>Cmax<\/jats:italic>\n                    ), and concentrations 10- and 100-fold above.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    In a human immunodeficiency virus (HIV) negative and a positive rifampicin-associated DRESS with positive\n                    <jats:italic>ex vivo<\/jats:italic>\n                    IFN-\u03b3 ELISpot assay, use of 10- and 100-fold\n                    <jats:italic>Cmax<\/jats:italic>\n                    drug concentrations decreased spot forming units\/million cells by 32\u2013100%, and this corresponded to cell cytotoxicity of more than 40 and 20% using an LDH assay and 7-AAD cell viability staining, respectively. The other antimicrobials (ceftriaxone, flucloxacillin, piperacillin\/tazobactam, and isoniazid) tested in healthy controls showed similar dose-dependent increased cytotoxicity using the LDH assay, but cytotoxicity remained lower than 40% for all\n                    <jats:italic>Cmax<\/jats:italic>\n                    and 10-fold\n                    <jats:italic>Cmax<\/jats:italic>\n                    drug concentrations except flucloxacillin. All 100-fold\n                    <jats:italic>Cmax<\/jats:italic>\n                    concentrations resulted in cell death &amp;gt;40% (median 57%), except for isoniazid. 7-AAD cell viability staining also confirmed an increase in lymphocyte death in PBMCs incubated with 10-fold and 100-fold above\n                    <jats:italic>Cmax<\/jats:italic>\n                    for ceftriaxone, and flucloxacillin; however, piperacillin\/tazobactam and isoniazid indicated no differences in percentages of viable lymphocytes across concentrations tested.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    The LDH cytotoxicity and 7-AAD cell viability staining techniques both demonstrate increased cell death corresponding to a loss in ELISpot sensitivity, with use of higher antimicrobial drug concentrations for\n                    <jats:italic>ex vivo<\/jats:italic>\n                    diagnostic IFN-\u03b3 ELISpot assays. For all the antimicrobials evaluated, the use of\n                    <jats:italic>Cmax<\/jats:italic>\n                    and 10-fold\n                    <jats:italic>Cmax<\/jats:italic>\n                    concentrations impacts cell viability and potentially affects ELISpot performance. These findings inform future approaches for\n                    <jats:italic>ex vivo<\/jats:italic>\n                    diagnostics such as IFN-\u03b3 release ELISpot.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2021.640012","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T03:37:54Z","timestamp":1628566674000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Dose Dependent Antimicrobial Cellular Cytotoxicity\u2014Implications for ex vivo Diagnostics"],"prefix":"10.3389","volume":"12","author":[{"given":"Ana","family":"Copaescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuti","family":"Choshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Pedretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Effie","family":"Mouhtouris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Trubiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,10]]},"reference":[{"key":"B1","unstructured":"LDH-cytotoxicity Assay Kit II2019"},{"key":"B2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/s0140-6736(18)32218-9","article-title":"Antibiotic Allergy","volume":"393","author":"Blumenthal","year":"2019","journal-title":"The Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.toxlet.2020.01.018","article-title":"Metabolomics Describes Previously Unknown Toxicity Mechanisms of Isoniazid and Rifampicin","volume":"322","author":"Combrink","year":"2020","journal-title":"Toxicol. Lett."},{"key":"B4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ymeth.2005.11.006","article-title":"Measurement of Cytokine Release at the Single Cell Level Using the ELISPOT Assay","volume":"38","author":"Cox","year":"2006","journal-title":"Methods"},{"key":"B5","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1124\/jpet.111.190900","article-title":"Characterization of the Antigen Specificity of T-Cell Clones from Piperacillin-Hypersensitive Patients with Cystic Fibrosis","volume":"341","author":"El-Ghaiesh","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B6","article-title":"Assays for Cell Viability, Proliferation and Function","volume-title":"Molecular Probes\u2122 Handbook","author":"Fisher Scientific","year":"2010"},{"key":"B7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/7651_2014_111","article-title":"ELISPOT Techniques","volume":"1304","author":"Ji","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1097\/qad.0000000000000345","article-title":"HLA Class I Restricted CD8+ and Class II Restricted CD4+ T Cells Are Implicated in the Pathogenesis of Nevirapine Hypersensitivity","volume":"28","author":"Keane","year":"2014","journal-title":"AIDS"},{"key":"B9","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/icb.2011.34","article-title":"High\u2010avidity, high\u2010IFN\u03b3\u2010producing CD8 T\u2010cell Responses Following Immune Selection during HIV\u20101 Infection","volume":"90","author":"Keane","year":"2012","journal-title":"Immunol. Cel Biol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1016\/j.jaip.2020.07.005","article-title":"Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go?","volume":"8","author":"Lehloenya","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jaip.2017.01.025","article-title":"Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice","volume":"5","author":"Peter","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B12","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/j.1398-9995.2008.01674.x","article-title":"Detection and Quantification of Drug-specific T Cells in Penicillin Allergy","volume":"64","author":"Rozieres","year":"2009","journal-title":"Allergy"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1586\/erv.12.125","article-title":"Pushing the Frontiers of T-Cell Vaccines: Accurate Measurement of Human T-Cell Responses","volume":"11","author":"Saade","year":"2012","journal-title":"Expert Rev. Vaccin."},{"key":"B14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/0022-1759(83)90091-1","article-title":"A Solid-phase Immunoenzymatic Technique for the Enumeration of Specific Antibody-Secreting Cells","volume":"57","author":"Sedgwick","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"B15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.14712\/23362936.2018.3","article-title":"Evaluation of IFN-Gamma Enzyme-Linked Immunospot Assay (ELISPOT) as a First-Line Test in the Diagnosis of Non-immediate Hypersensitivity to Amoxicillin and Penicillin","volume":"119","author":"Sedlackova","year":"2018","journal-title":"Prague Med. Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1007\/s10616-016-9998-6","article-title":"LDH, Proliferation Curves and Cell Cycle Analysis Are the Most Suitable Assays to Identify and Characterize New Phytotherapeutic Compounds","volume":"68","author":"Specian","year":"2016","journal-title":"Cytotechnology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2340\/00015555-1386","article-title":"The Potential of Using Enzyme-Linked Immunospot to Diagnose Cephalosporin-Induced Maculopapular Exanthems","volume":"93","author":"Tanvarasethee","year":"2013","journal-title":"Acta Derm Venerol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.jaip.2017.09.004","article-title":"The Combined Utility of Ex Vivo IFN-\u03b3 Release Enzyme-Linked ImmunoSpot Assay and In Vivo Skin Testing in Patients with Antibiotic-Associated Severe Cutaneous Adverse Reactions","volume":"6","author":"Trubiano","year":"2018","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B19","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/toxsci\/kfw218","article-title":"From the Cover: Characterization of Isoniazid-specific T-Cell Clones in Patients with Anti-tuberculosis Drug-Related Liver and Skin Injury","volume":"155","author":"Usui","year":"2017","journal-title":"Toxicol. Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ab.2012.07.005","article-title":"7-Aminoactinomycin D for Apoptosis Staining in Flow Cytometry","volume":"429","author":"Zembruski","year":"2012","journal-title":"Anal. Biochem."}],"updated-by":[{"DOI":"10.3389\/fphar.2021.758192","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000}}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.640012\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T04:19:15Z","timestamp":1630988355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.640012\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,10]]},"references-count":20,"alternative-id":["10.3389\/fphar.2021.640012"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.640012","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,10]]},"article-number":"640012"}}